X4 Pharma shareholders approve 1.5M share equity plan increase, elect three directors at 2026 annual meeting

Proposal 4. Approval, on a non-binding, advisory basis of the compensation of the Company’s named executive officers The Company’s stockholders approved, by a non-binding “say-on-pay” vote, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 70,932,142 20,692 5,420,569 6,474,104

Proposal 3. Approval of the Second Amended and Restated 2017 Equity Incentive Plan The Company’s stockholders approved the Second Amended and Restated 20217 Equity Incentive Plan. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 58,679,552 9,711 17,684,140 6,474,104

Proposal 2. Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes cast were as follows: FOR ABSTAIN AGAINST BROKER NON-VOTES 82,734,674 43,841 68,992 —

Proposal 1. Election of the three Class III director nominees to serve until the 2029 Annual Meeting of Stockholders The Company’s stockholders elected the persons listed below as director, to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified or until their earlier death, resignation of removal. The votes cast were as follows: Nominees For Withheld Broker non-votes Gary J. Bridger, Ph.D. 72,863,269 3,510,134 6,474,104 Françoise De Craecker 73,419,383 2,954,020 6,474,104 Michael S. Wyzga 71,679,834 4,693,569 6,474,104